We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Gout Increases Risk of Advanced Chronic Kidney Disease

By LabMedica International staff writers
Posted on 11 Sep 2019
Chronic kidney disease (CKD) is a major public health epidemic, with at least 1 in 10 individuals having some degree of kidney impairment, contributing substantially to adverse clinical and economic outcomes.

Gout is the most common inflammatory arthritis, which causes severe pain and suffering due to a build-up of uric acid in joints. More...
It affects almost 2.5 % of the adult population and causes significant pain and disability due to its effects on joints, tendons and bone.

A team of scientists working with the University of Limerick (Limerick, Ireland) analyzed the risk of advanced chronic kidney disease (CKD) in 68,897 gout patients followed for an average of 3.7 years and compared them to 554,964 patients without gout. The primary and secondary outcome measures: Advanced CKD was defined as first occurrence of: (1) dialysis, kidney transplant, diagnosis of end-stage kidney disease (ESKD) or stage 5 CKD; (2) estimated glomerular filtration rate (eGFR) <10 mL/min/1.73 m²; (3) doubling of serum creatinine from baseline and (4) death associated with CKD.

The team reported that advanced CKD incidence was higher for patients with gout (8.54 per 1000 patient-years) versus without gout (4.08). Gout was associated with higher advanced CKD risk in both unadjusted analysis (Hazard ratio [HR], 2.00) and after adjustment (HR, 1.29). Association was strongest for ESKD (HR, 2.13) and was present for eGFR <10 mL/min/1.73 m² (HR, 1.45) and serum creatinine doubling (HR, 1.13), but not CKD-associated death (HR, 1.14) Association of gout with advanced CKD was replicated in propensity-score matched analysis (HR, 1.23) and analysis limited to patients with incident gout (HR, 1.28).

Austin G. Stack, MBBCh, MD, MSc, FASN, FRCPI, a Professor of Medicine and the lead author of the study, said, “We discovered that patients who suffered from gout had a 29% higher risk of advanced CKD compared to those without gout. Indeed when we analyzed each of the components of advanced kidney disease, we found that in general gout patients were at higher risk of deterioration in kidney function compared to those without. Astonishingly, when we looked at the risk of kidney failure and those who needed dialysis or a kidney transplant, we found that gouts patients had more than a 200% higher risk of kidney failure than those without gout.” The study was published on August 28, 2019, in the journal BMJ Open.

Related Links:
University of Limerick


Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Alcohol Testing Device
Dräger Alcotest 7000
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.